Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant
Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani’s NanoPortal platform for chronic weight management. Vivani has initiated a Phase 1 clinical study of the implant, while Novo Nordisk assesses semaglutide in this drug delivery format. The partnership focuses on an implantable GLP-1 approach that could offer an alternative to pills and injections for obesity treat…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
